All air passengers regardless of citizenship or vaccination status, must show a negative result of a COVID-19 viral test or documentation of recovery from COVID-19 before they board a flight to the United States.
As determined by the CDC, people are considered fully vaccinated two weeks after their second dose in a two-dose series, or two weeks after a single dose vaccine.
- Mixed-dose vaccine will be accepted.
- Some participants in vaccine clinical trials will be considered fully vaccinated.
As determined by the CDC, accepted vaccines are:
- All FDA approved and authorized vaccines: Janssen/J&J (single dose), Pfizer-BioNTech, and Moderna.
- Vaccines that have an Emergency Use Listing from the World Health Organization (WHO) will be accepted: Janssen/J&J (single dose), Pfizer-BioNTech, Moderna, AstraZeneca, Covishield, BIBP/Sinopharm, and Sinovac.
- AstraZeneca used in Canada and Europe will be accepted
Exceptions to being vaccinated are limited to:
- Children under 18
- Certain COVID-19 vaccine clinical trial participants
- Those with medical contraindications to vaccines
- Those authorized to travel for humanitarian reasons
- Those who are traveling on non-tourist visas from countries with low COVID-19 vaccine availability (as determined by the CDC)
Those who receive an exception will be required to attest they will comply with applicable health requirements, including, with limited exceptions, a requirement that they be vaccinated against COVID-19 in the U.S. if they intend to stay more than 60 days. This attestation will also require that traveler show proof of arrangements to become fully vaccinated against COVID-19 within 60 days of arriving in the United States or as soon thereafter as is medically appropriate.
All air passengers to the United States will also be required to provide contact information to airlines before boarding flights to the United States. According to the CDC, this strengthens a travel process already in place to rapidly identify and contact people in the U.S. who may have been exposed to a communicable disease, such as COVID-19. Access to travelers’ contact information will allow U.S. federal, state, and local health departments and agencies to share appropriate health and public health information necessary to help keep the public safe.